This new article publication from Acta Pharmaceutica Sinica B, discusses how ALKBH3-regulated m 1 A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells.

A Carnegie Mellon University-led team is receiving $5.4 million from the Defense Advanced Research Projects Agency to develop technologies for transporting drug molecules in red blood cells.